6YZ Stock Overview
New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
New Horizon Health Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.26 |
| 52 Week High | HK$3.78 |
| 52 Week Low | HK$1.95 |
| Beta | 1.38 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -36.16% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -37.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6YZ | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | -1.2% |
| 1Y | -36.2% | 1.3% | 1.8% |
Return vs Industry: 6YZ underperformed the German Healthcare industry which returned 0.6% over the past year.
Return vs Market: 6YZ underperformed the German Market which returned -0.9% over the past year.
Price Volatility
| 6YZ volatility | |
|---|---|
| 6YZ Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 5.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6YZ has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 6YZ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 1,041 | Yeqing Zhu | ir.newhorizonbio.com |
New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People’s Republic of China. Its products include ColoClear, an early screening products for colon cancer; Pupu Tube, a fecal occult blood self test product; and UU Tube, a helicobacter pylori self-test products. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities.
New Horizon Health Limited Fundamentals Summary
| 6YZ fundamental statistics | |
|---|---|
| Market cap | €936.79m |
| Earnings (TTM) | €14.50m |
| Revenue (TTM) | €176.80m |
69.0x
P/E Ratio5.7x
P/S RatioIs 6YZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6YZ income statement (TTM) | |
|---|---|
| Revenue | CN¥1.36b |
| Cost of Revenue | CN¥153.40m |
| Gross Profit | CN¥1.21b |
| Other Expenses | CN¥1.10b |
| Earnings | CN¥111.70m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.25 |
| Gross Margin | 88.74% |
| Net Profit Margin | 8.20% |
| Debt/Equity Ratio | 12.7% |
How did 6YZ perform over the long term?
See historical performance and comparison